Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
patent challenge
Pharma
FTC launches investigation into Teva's inhaler patents: report
While other drugmakers have relented in the face of the U.S. FTC's assault on “junk” patents in the FDA’s Orange Book, Teva has stood its ground.
Fraiser Kansteiner
Jul 2, 2024 10:02am
Teva notches loss in inhaler patent case against Amneal
Jun 12, 2024 9:35am
FTC targets Novo's Ozempic among 300-plus 'junk' patents
May 1, 2024 7:30am
Merck challenges Johns Hopkins University's Keytruda patents
Mar 14, 2024 7:30am
GSK, Amneal and Kaleo walk back patents after FTC's challenge
Dec 21, 2023 11:08am
FDA endorses Avadel's Lumryz, a major threat to Jazz's Xyrem
May 2, 2023 8:00am
